Challenges with Estimating Long-Term Overall Survival in Extensive Stage Small-Cell Lung Cancer: A Validation-Based Case Study

References

• Latimer N. NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials-extrapolation with patient-level data. Report by the Decision Support Unit; 2011.
   Google Scholar
• Rutherford MJ, Lambert PC, Sweeting MJ, et al. NICE DSU technical support document 21. In: Flexible Methods for Survival Analysis. Leicester, UK: Department of Health Sciences, University of Leicester; 2020:1–97.
   Google Scholar
• Carta A, Conversano C. On the use of Markov models in pharmacoeconomics: pros and cons and implications for policy makers. Front Public Health. 2020;8:569500. doi:10.3389/fpubh.2020.569500
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535–1546. doi:10.1056/NEJMoa1910836
   PubMed Web of Science ®Google Scholar
• Damuzzo V, Agnoletto L, Leonardi L, Chiumente M, Mengato D, Messori A. Analysis of survival curves: statistical methods accounting for the presence of long-term survivors. Front Oncol. 2019;9:453. doi:10.3389/fonc.2019.00453
   Web of Science ®Google Scholar
• Basumallik N, Agarwal M. Small cell lung cancer. In: StatPearls. StatPearls Publishing; 2023. Available from: http://www.ncbi.nlm.nih.gov/books/NBK482458/. Accessed January 19, 2024.
   Google Scholar
• Demedts IK, Vermaelen KY, Meerbeeck JPV. Treatment of extensive-stage small cell lung carcinoma: current status and future prospects. Eur Respir J. 2010;35(1):202–215. doi:10.1183/09031936.00105009
   PubMed Web of Science ®Google Scholar
• Dingemans AM, Früh M, Ardizzoni A, et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆. Ann Oncol. 2021;32(7):839–853. doi:10.1016/j.annonc.2021.03.207
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229. doi:10.1056/NEJMoa1809064
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929–1939. doi:10.1016/S0140-6736(19)32222-6
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Chen Y, Reinmuth N, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO open. 2022;7(2):100408. doi:10.1016/j.esmoop.2022.100408
   PubMed Web of Science ®Google Scholar
• Saida Y, Watanabe S, Kikuchi T. Extensive-stage small-cell lung cancer: current landscape and future prospects. Onco Targets Ther. 2023;16:657–671. doi:10.2147/OTT.S272552
   Web of Science ®Google Scholar
• Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51–65. doi:10.1016/S1470-2045(20)30539-8
   PubMed Web of Science ®Google Scholar
• Lambert PC. Modeling of the cure fraction in survival studies. Stata J. 2007;7(3):351–375. doi:10.1177/1536867X0700700304
   Web of Science ®Google Scholar
• Palmer S, Borget I, Friede T, et al. A guide to selecting flexible survival models to inform economic evaluations of cancer immunotherapies. Value Health. 2022;26(2):185–192.
   Web of Science ®Google Scholar
• Dafni U. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes. 2011;4(3):363–371. doi:10.1161/CIRCOUTCOMES.110.957951
   PubMed Web of Science ®Google Scholar
• Smare C, Lakhdari K, Doan J, Posnett J, Johal S. Evaluating partitioned survival and Markov decision-analytic modeling approaches for use in cost-effectiveness analysis: estimating and comparing survival outcomes. Pharmacoeconomics. 2020;38(1):97–108. doi:10.1007/s40273-019-00845-x
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Clinical study report - a Phase III, randomized, multicenter, open-label, comparative study to determine the efficacy of durvalumab or durvalumab and tremelimumab in combination with platinum-based chemotherapy for the first-line treatment in patients with Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN); 2019.
   Google Scholar
• Johal S, Fischer C, Cawston H, Jiang H, Brannman L. The impact of response on survival in extensive-stage small-cell lung cancer in the CASPIAN study. EP14.04-002. IASLC 2022 World Conference on Lung Cancer (WCLC); 2022; Vienna, Austria.
   Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247. doi:10.1016/j.ejca.2008.10.026
   PubMed Web of Science ®Google Scholar
• Ouwens M, Mukhopadhyay P, Zhang Y, Huang M, Latimer N, Briggs A. Estimating lifetime benefits associated with immuno-oncology therapies: challenges and approaches for overall survival extrapolations. Pharmacoeconomics. 2019;37(9):1129–1138. doi:10.1007/s40273-019-00806-4
   PubMed Web of Science ®Google Scholar
• van OI, Ouwens M, Remiro-Azócar A, et al. Comparison of parametric survival extrapolation approaches incorporating general population mortality for adequate health technology assessment of new oncology drugs. Value Health. 2021;24(9):1294–1301. doi:10.1016/j.jval.2021.03.008
   Web of Science ®Google Scholar
• Khakwani A, Rich AL, Tata LJ, et al. Small-cell lung cancer in England: trends in survival and chemotherapy using the National Lung Cancer Audit. PLoS One. 2014;9(2):e89426. doi:10.1371/journal.pone.0089426
   Web of Science ®Google Scholar